Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

THOR - Synthorx Inc.

Previous close
67.99
0   0%

Share volume: 0
Last Updated: Wed 22 Jan 2020 06:00:00 AM CET
Biotechnology: -0.99%

PREVIOUS CLOSE
CHG
CHG%
$67.99
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
71%
Profitability 86%
Dept financing 3%
Liquidity 49%
Performance 79%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$67.99
P/E Ratio 
N/A
DAY RANGE
$67.99 - $67.99
EPS 
-$4.06
52 WEEK RANGE
$11.05 - $71.90
52 WEEK CHANGE
$395.19
MARKET CAP 
2.199 B
YIELD 
N/A
SHARES OUTSTANDING 
32.338 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$32,338,000
AVERAGE 10 VOLUME 
$420,113
AVERAGE 30 VOLUME 
$502,510
Company detail
CEO:
Region: US
Website: http://synthorx.com/
Employees: 38
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Synthorx, Inc. focuses on prolonging and improving lives of cancer and autoimmune disorder patients. Its product pipeline is comprised of THOR-707, IL-2 Synthorin, IL-10 Synthorin, and IL-15 Synthorin. The company was founded by Floyd E. Romesberg and Court R. Turner in 2014 and is headquartered in La Jolla, CA.

Recent news